Tamoxifen plus bromocriptine versus tamoxifen plus placebo in advanced breast cancer: results of a double blind multicentre clinical trial.
Eur J Cancer Clin Oncol
; 24(12): 1851-3, 1988 Dec.
Article
in En
| MEDLINE
| ID: mdl-3065085
ABSTRACT
We carried out a double blind multicentre clinical trial in which 171 patients with advanced breast cancer were randomized to receive tamoxifen (30 mg/day) + bromocriptine (5 mg/day) or tamoxifen + placebo. No difference was found in the overall response rates in the two groups (37.5% for placebo; 38% for bromocriptine) or in subgroups (breast tumours, lymph nodes, lung, bone, skin metastases). Tolerability was good in both groups. Within the limits of the statistical power of the test (80%), our results do not show any benefit when bromocriptine was added to tamoxifen.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Antineoplastic Combined Chemotherapy Protocols
Type of study:
Clinical_trials
Limits:
Female
/
Humans
Language:
En
Journal:
Eur J Cancer Clin Oncol
Year:
1988
Type:
Article
Affiliation country:
France